- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:31 | BlossomHill Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13:06 | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results | 58 | GlobeNewswire (Europe) | Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive... ► Artikel lesen | |
| Do | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | 635 | AFX News | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| BLOSSOMHILL THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | BlossomHill closes up 18% on strongest day since August IPO | 2 | Seeking Alpha | ||
| Di | BlossomHill Therapeutics bei H.C. Wainwright: Daten zum Hauptwirkstoff verbessern den Ausblick | 3 | Investing.com Deutsch | ||
| Di | Starke Studiendaten und Investorenkonferenz treiben Aktie von BlossomHill Therapeutics an | 1 | Investing.com Deutsch | ||
| Di | BlossomHill Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World ... | 1 | GlobeNewswire (USA) | ||
| 01.09. | JPMorgan nimmt Coverage von BlossomHill Therapeutics mit "Overweight" auf | 1 | Investing.com Deutsch | ||
| 01.09. | JPMorgan initiates BlossomHill Therapeutics stock with overweight | 1 | Investing.com | ||
| 31.08. | Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc. | 620 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx... ► Artikel lesen | |
| 18.08. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC | 514 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and... ► Artikel lesen | |
| 10.08. | BlossomHill Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.08. | BlossomHill Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Cancer drug developer BlossomHill slips after upsized IPO | 1 | Seeking Alpha | ||
| 07.08. | BlossomHill Therapeutics Aktie fällt bei Börsendebüt | 1 | Investing.com Deutsch | ||
| 07.08. | BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts | 1 | FierceBiotech | ||
| 07.08. | BlossomHill Therapeutics prices upsized IPO at $16, the midpoint of the range | 1 | Renaissance Capital | ||
| 07.08. | BlossomHill Therapeutics prices IPO at $16 per share | 1 | Investing.com | ||
| 07.08. | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering | 250 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 75,62 | 0,00 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| EDGEWISE THERAPEUTICS | 46,940 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| VERA THERAPEUTICS | 34,290 | +0,06 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,470 | +0,04 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| ERASCA | 15,360 | 0,00 % | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | ||
| SUMMIT THERAPEUTICS | 17,715 | -0,03 % | UBS reiterates Summit Therapeutics stock rating on trial data | ||
| BIOAFFINITY TECHNOLOGIES | 8,880 | +1,49 % | bioAffinity Technologies, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,650 | +0,12 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| PARABILIS MEDICINES | 40,880 | 0,00 % | Parabilis auf Morgan-Stanley-Konferenz: Umfassende Strategie für Beta-Catenin-Plattform | ||
| PRAXIS PRECISION MEDICINES | 310,74 | +0,09 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 42,740 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| ABSCI | 9,255 | -0,16 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| ENLIVEN THERAPEUTICS | 50,21 | 0,00 % | Enliven Therapeutics auf Morgan Stanley Konferenz: Liquidität, Studien und die CML-Marktchance | ||
| RELAY THERAPEUTICS | 19,180 | 0,00 % | Relay Therapeutics auf Morgan Stanley Konferenz: Mehrere Entwicklungschancen mit einem Wirkstoff |
Das Unternehmen BLOSSOMHILL THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 26,795 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BLOSSOMHILL THERAPEUTICS INC finden Sie auf Wallstreet Online.